Fausto Rosa1,2, Federica Galiandro3, Riccardo Ricci4,5, Dario Di Miceli6, Fabio Longo3, Giuseppe Quero3, Antonio Pio Tortorelli3, Sergio Alfieri3,4. 1. Digestive Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy. fausto.rosa@policlinicogemelli.it. 2. Università Cattolica del Sacro Cuore, Rome, Italy. fausto.rosa@policlinicogemelli.it. 3. Digestive Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, 00168, Rome, Italy. 4. Università Cattolica del Sacro Cuore, Rome, Italy. 5. Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. 6. General Surgery, Ospedale Buccheri-La Ferla, Palermo, Italy.
Abstract
BACKGROUND: Selection criteria and prognostic factors for patients with advanced gastric cancer (AGC) undergoing cytoreductive surgery (CRS) plus hyperthermic intra-operative peritoneal chemotherapy (HIPEC) have not been well defined and the literature data are not homogeneous. The aim of this study was to compare prognostic factors influencing overall (OS) and disease-free survival (DFS) in a population of patients affected by AGC with surgery alone and surgery plus HIPEC, both with curative (PCI, Peritoneal Carcinomatosis Index >1) and prophylactic (PCI=0) intent. METHODS: A retrospective analysis of a prospectively collected database was conducted in patients affected by AGC from January 2006 to December 2015. Uni- and multivariate analyses of prognostic factors were performed. RESULTS: A total of 85 patients with AGC were analyzed. Five-year OS for surgery alone, CRS plus curative HIPEC, and surgery plus prophylactic HIPEC groups was 9%, 27%, and 33%, respectively. Statistical significance was reached comparing both prophylactic HIPEC vs surgery alone group (p = 0.05), curative HIPEC vs surgery alone group (p = 0.03), and curative vs prophylactic HIPEC (p = 0.04). Five-year DFS for surgery alone, CRS + curative HIPEC, and surgery + prophylactic HIPEC groups was 9%, 20%, and 30%, respectively. Statistical significance was reached comparing both prophylactic HIPEC vs surgery alone group (p < 0.0001), curative HIPEC vs surgery alone group (p = 0.008), and curative vs prophylactic HIPEC (p = 0.05). CONCLUSIONS: Patients with AGC undergoing surgery plus HIPEC had a better OS and DFS with respect to patients treated with surgery alone.
BACKGROUND: Selection criteria and prognostic factors for patients with advanced gastric cancer (AGC) undergoing cytoreductive surgery (CRS) plus hyperthermic intra-operative peritoneal chemotherapy (HIPEC) have not been well defined and the literature data are not homogeneous. The aim of this study was to compare prognostic factors influencing overall (OS) and disease-free survival (DFS) in a population of patients affected by AGC with surgery alone and surgery plus HIPEC, both with curative (PCI, Peritoneal Carcinomatosis Index >1) and prophylactic (PCI=0) intent. METHODS: A retrospective analysis of a prospectively collected database was conducted in patients affected by AGC from January 2006 to December 2015. Uni- and multivariate analyses of prognostic factors were performed. RESULTS: A total of 85 patients with AGC were analyzed. Five-year OS for surgery alone, CRS plus curative HIPEC, and surgery plus prophylactic HIPEC groups was 9%, 27%, and 33%, respectively. Statistical significance was reached comparing both prophylactic HIPEC vs surgery alone group (p = 0.05), curative HIPEC vs surgery alone group (p = 0.03), and curative vs prophylactic HIPEC (p = 0.04). Five-year DFS for surgery alone, CRS + curative HIPEC, and surgery + prophylactic HIPEC groups was 9%, 20%, and 30%, respectively. Statistical significance was reached comparing both prophylactic HIPEC vs surgery alone group (p < 0.0001), curative HIPEC vs surgery alone group (p = 0.008), and curative vs prophylactic HIPEC (p = 0.05). CONCLUSIONS:Patients with AGC undergoing surgery plus HIPEC had a better OS and DFS with respect to patients treated with surgery alone.
Entities:
Keywords:
Gastric cancer; HIPEC; Peritoneal carcinomatosis; Surgery
Authors: A C Sayag-Beaujard; Y Francois; O Glehen; B Sadeghi-Looyeh; J Bienvenu; G Panteix; F Garbit; E Grandclément; J Vignal; F N Gilly Journal: Anticancer Res Date: 1999 Mar-Apr Impact factor: 2.480
Authors: Gian Luca Baiocchi; Daniele Marrelli; Giuseppe Verlato; Paolo Morgagni; Simone Giacopuzzi; Arianna Coniglio; Alberto Marchet; Fausto Rosa; Michela Giulii Capponi; Alberto Di Leo; Luca Saragoni; Luca Ansaloni; Fabio Pacelli; Donato Nitti; Domenico D'Ugo; Franco Roviello; Guido A M Tiberio; Stefano M Giulini; Giovanni De Manzoni Journal: Ann Surg Oncol Date: 2014-02-14 Impact factor: 5.344
Authors: F N Gilly; P Y Carry; A C Sayag; A Brachet; G Panteix; B Salle; J Bienvenu; G Burgard; B Guibert; V Banssillon Journal: Hepatogastroenterology Date: 1994-04
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Michel Adamina; Maxime Warlaumont; Martin D Berger; Silvio Däster; Raphaël Delaloye; Antonia Digklia; Beat Gloor; Ralph Fritsch; Dieter Koeberle; Thibaud Koessler; Kuno Lehmann; Phaedra Müller; Ralph Peterli; Frédéric Ris; Thomas Steffen; Christian Stefan Weisshaupt; Martin Hübner Journal: Cancers (Basel) Date: 2022-09-01 Impact factor: 6.575